Clinical Trials Browser

Phase 2 × INDUSTRY × Lymphoma, B-Cell, Marginal Zone × Clear all

NCT07387471 2026-05-29

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT04849416 2026-02-06

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Phase 2 Completed

87 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04116437 2026-01-28

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Phase 2 Completed

LymphoidOther hematologic neoplasm

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03105336 2025-12-23

ZUMA-5

Phase 2 Completed

159 enrolled 27 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03888105 2025-10-15

ELM-2

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03144674 2025-07-11

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Phase 2 Completed

110 enrolled 18 charts

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT04849351 2025-04-06

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Phase 2 Completed

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03768505 2024-12-31

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Phase 2 Terminated

169 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05008055 2024-12-20

CAPITAL

Phase 2 Completed

30 enrolled 15 charts

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03520920 2024-10-26

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Phase 2 Completed

41 enrolled 25 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03846427 2024-10-26

MAGNOLIA

Phase 2 Completed

68 enrolled 28 charts 1 FDA

Lymphoma, B-Cell, Marginal Zone

NCT04298879 2024-06-05

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Phase 2 Completed

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT00081809 2023-09-28

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

Phase 2 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03364231 2023-06-23

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

21 enrolled 14 charts

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04431089 2021-01-28

Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma

Phase 2 Unknown

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT01980628 2019-10-16

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Phase 2 Completed

63 enrolled 8 charts

Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01282424 2019-07-11

DELTA

Phase 2 Completed

125 enrolled 25 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone